Expedition Therapeutics

Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases. The company advances EXPD-101, an oral once-daily inhibitor of DPP1, which targets neutrophilic inflammation and is positioned for chronic obstructive pulmonary disease (COPD) and other neutrophil-driven indications. It pursues global clinical development of EXPD-101 while exploring expansion into bronchiectasis, neutrophilic asthma, and related conditions. The leadership team combines expertise in drug discovery, translational science, clinical development, and business strategy. Expedition Therapeutics operates a model that integrates in-licensing of external innovation with internally generated programs.

Domain

expeditiontx.com

Employees

1-10

Last Funding

$165.0M

Founded

2023

Frequently Asked Questions

What technologies does Expedition Therapeutics use?+

Expedition Therapeutics uses 21 technologies including Elementor, Font Awesome, reCAPTCHA.

What industry is Expedition Therapeutics in?+

Expedition Therapeutics operates in the Biotechnology industry.

Where is Expedition Therapeutics based?+

Expedition Therapeutics is headquartered in United States.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026